APA (7th ed.) Citation

K, Y., T, M., MA, D., J, M., M, C., T, F., . . . P, M. (2026). Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone. Future oncology (London, England), 1. https://doi.org/10.1080/14796694.2026.2683336

Chicago Style (17th ed.) Citation

K, Yong, et al. "Plain Language Summary of Publication of How Long People with Relapsed Multiple Myeloma Lived After Treatment in the IKEMA Study: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone." Future Oncology (London, England) 2026: 1. https://doi.org/10.1080/14796694.2026.2683336.

MLA (9th ed.) Citation

K, Yong, et al. "Plain Language Summary of Publication of How Long People with Relapsed Multiple Myeloma Lived After Treatment in the IKEMA Study: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone." Future Oncology (London, England), 2026, p. 1, https://doi.org/10.1080/14796694.2026.2683336.